Pozen (POZN) says the U.S. Court of Appeals has upheld the Texas District Court's ruling that...

|By:, SA News Editor

Pozen (POZN) says the U.S. Court of Appeals has upheld the Texas District Court's ruling that had originally found in favor of POZN against several generic pharmaceutical companies which had filed Abbreviated New Drug Applications seeking FDA approval to market generic copies of Treximet. Treximet is marketed by POZN's exclusive U.S. licensee, GlaxoSmithKline (GSK).